Corporate ProfileG1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company’s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Stock Information

GTHX (Common Stock)



08/14/18 4:00 p.m. ET

Stock chart for: GTHX.O.  Currently trading at $57.06 with a 52 week high of $64.83 and a 52 week low of $12.64.
Recent NewsMore >>
08/08/18G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial UpdatePrinter Friendly Version
08/07/18G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018Printer Friendly Version
08/01/18G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018Printer Friendly Version
07/09/18G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General CounselPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.